Antev is a clinical stage speciality pharmaceutical company with a primary focus is on prostate cancer and urology with an interest in women's health. We are developing a single compound in multiple indications: Teverelix, a long acting injectable peptide GnRH antagonist. The lead indication is prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance.
106 New Bond Street
London, W1S 1DN
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020